ELVNEnliven Therapeutics, Inc.

Healthcare
$40.98+116% 1Y

Price

+116%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 5% of companies
8/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for ELVN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Our discovery process combines deep insights into clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs.

In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR

P/En/a
Market value$3.51B
1 year+116%
5 years+149%

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 11, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Aug 5, 2026Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update.Earnings release · press release
  2. Jun 12, 2026On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein …Material agreement entered · Form 8-K
  3. Jun 11, 2026On June 11, 2026, the Company announced updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with CML and key outcomes from the Company’s End-of-Phase 1 meeting with the U.S. Food and Drug Administration (the “FDA”)Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #126 of 196 by RyuScore

Compare peers
IDYA+0.21%
IDEAYA Biosciences, Inc.
BEAM+4.6%
Beam Therapeutics Inc.
GPCR-0.58%
Structure Therapeutics Inc.
DYN+1.7%
Dyne Therapeutics, Inc.
QURE+0.22%
uniQure N.V.
TLX+1.9%
Telix Pharmaceuticals Limited